{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:49:13Z","timestamp":1789044553058,"version":"build-2803163510"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Stiripentol is a strong inhibitor of CYP2C19 and CYP3A4. This study compared the effect of stiripentol on the pharmacokinetics of clobazam and N-desmethyl-clobazam (NCLB; an active metabolite of clobazam) between different CYP2C19 phenotypes. We also evaluated the clinical impact of CYP2C19 phenotypes in Japanese patients with Dravet syndrome receiving a combination of valproic acid, clobazam, and stiripentol.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We retrospectively reviewed 241 blood samples from 64 patients (aged 1\u201340 years) and calculated the concentration\/dose (CD) ratio [serum level (ng\/mL) divided by dose (mg\/kg)] for clobazam and NCLB. Based on their CYP2C19 genotypes, patients were classified as extensive metabolizers (EM group: CYP2C19*1\/*1, *1\/*2, or *1\/*3) or poor metabolizers (PM group: CYP2C19*2\/*2, *3\/*3, or *2\/*3). We also reviewed the clinical records of 56 patients who commenced stiripentol therapy and calculated the retention rate for stiripentol therapy over an observation period of 208 weeks.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Concomitant administration of stiripentol led to a marked increase in the CD ratio of clobazam (1.8-fold in the EM group and 1.5-fold in the PM group). In addition, stiripentol increased the CD ratio of NCLB by 6.6-fold in the EM group, but decreased it by 0.7-fold in the PM group. The estimated retention rate with stiripentol therapy was higher, and the duration of retention was longer in the EM group than in the PM group (1378 versus 933 days, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). In patients with the PM phenotype, the adjusted hazard ratio for ceasing stiripentol therapy was 6.7 (95% confidence interval: 1.8\u201324.7, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.005).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The effect of stiripentol on the pharmacokinetics of NCLB was significantly different between patients with the EM and PM phenotypes, which could influence the clinical response of Japanese patients with Dravet syndrome receiving the combination of valproic acid, clobazam, and stiripentol.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000676","type":"journal-article","created":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T08:41:02Z","timestamp":1563439262000},"page":"302-308","source":"Crossref","is-referenced-by-count":9,"title":["Impact of CYP2C19 Phenotypes on Clinical Efficacy of Stiripentol in Japanese Patients With Dravet Syndrome"],"prefix":"10.1097","volume":"42","author":[{"given":"Yoshiaki","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Department of Clinical Research, NHO, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders;"},{"name":"Department of Clinical Pharmaceutics, Graduate School of Pharmaceutical Sciences, University of Shizuoka; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukitoshi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, NHO, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders;"},{"name":"Department of Clinical Pharmaceutics, Graduate School of Pharmaceutical Sciences, University of Shizuoka; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, NHO, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, NHO, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Kagawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmaceutics, Graduate School of Pharmaceutical Sciences, University of Shizuoka; and"},{"name":"Laboratory of Clinical Pharmacokinetics and Drug Safety, Shizuoka General Hospital, Shizuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, NHO, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/B978-0-444-52891-9.00065-8","article-title":"Dravet syndrome (severe myoclonic epilepsy in infancy)","volume":"111","author":"Dravet","year":"2013","journal-title":"Handb Clin Neurol."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1124\/dmd.32.11.1279","article-title":"In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19","volume":"32","author":"Giraud","year":"2004","journal-title":"Drug Metab Dispos."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/FTD.0b013e31827ada88","article-title":"Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies","volume":"35","author":"de Leon","year":"2013","journal-title":"Ther Drug Monit."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/FTD.0000000000000272","article-title":"Therapeutic drug monitoring of clobazam and its metabolite-impact of age and comedication on pharmacokinetic variability","volume":"38","author":"Burns","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(00)03157-3","article-title":"Stiripentol in severe myoclonic epilepsy in infancy: a randomized placebo-controlled syndrome-dedicated trial. STICLO study group","volume":"356","author":"Chiron","year":"2000","journal-title":"Lancet."},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/FTD.0b013e318283b49a","article-title":"Influence of CYP2C19 polymorphism and concomitant antiepileptic drugs on serum clobazam and N desmethyl-clobazam concentrations in patients with epilepsy","volume":"35","author":"Yamamoto","year":"2013","journal-title":"Ther Drug Monit."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2133\/dmpk.18.48","article-title":"Bioinformatics research on inter-racial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19","volume":"18","author":"Shimizu","year":"2003","journal-title":"Drug Metab Pharmacokinet."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.eplepsyres.2014.02.008","article-title":"Effectiveness of add-on stiripentol to clobazam and valproate in Japanese patients with Dravet syndrome: additional supportive evidence","volume":"108","author":"Inoue","year":"2014","journal-title":"Epilepsy Res."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40262-014-0223-5","article-title":"Pharmacokinetics of clobazam and N-desmethylclobazam in children with dravet syndrome receiving concomitant stiripentol and valproic Acid","volume":"54","author":"Jullien","year":"2015","journal-title":"Clin Pharmacokinet."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/j.1528-1167.2009.02179.x","article-title":"Stiripentol open study in Japanese patients with Dravet syndrome","volume":"50","author":"Inoue","year":"2009","journal-title":"Epilepsia."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1177\/0091270004269015","article-title":"Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes","volume":"44","author":"Yasui-Furukori","year":"2004","journal-title":"J Clin Pharmacol."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejphar.2010.12.037","article-title":"Interactions between modulators of the GABA(A) receptor: stiripentol and benzodiazepines","volume":"654","author":"Fisher","year":"2011","journal-title":"Eur J Pharmacol."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eplepsyres.2016.05.012","article-title":"Patients with dravet syndrome in the era of stiripentol: a French cohort cross-sectional study","volume":"125","author":"De Liso","year":"2016","journal-title":"Epilepsy Res."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1111\/epi.14536","article-title":"Do children with Dravet syndrome continue to benefit from stiripentol for long through adulthood?","volume":"59","author":"Chiron","year":"2018","journal-title":"Epilepsia."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.braindev.2014.04.003","article-title":"Effect of CYP2C19 polymorphisms on stiripentol administration in Japanese cases of Dravet syndrome","volume":"37","author":"Kouga","year":"2015","journal-title":"Brain Dev."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1111\/epi.12303","article-title":"Stiripentol in Dravet syndrome: results of a retrospective U.S. study","volume":"54","author":"Wirrell","year":"2013","journal-title":"Epilepsia."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00228-014-1719-5","article-title":"Impact of cytochrome P450 inducers with or without inhibitors on the serum clobazam level in patients with antiepileptic polypharmacy","volume":"70","author":"Yamamoto","year":"2014","journal-title":"Eur J Clin Pharmacol."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/FTD.0000000000000274","article-title":"Perampanel serum concentrations in adults with epilepsy: effect of dose, age, sex, and concomitant anti-epileptic drugs","volume":"38","author":"Patsalos","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.eplepsyres.2016.12.014","article-title":"Add-on stiripentol elevates serum valproate levels in patients with or without concomitant topiramate therapy","volume":"130","author":"Jogamoto","year":"2017","journal-title":"Epilepsy Res."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1111\/epi.13802","article-title":"Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: a comparison of free non-protein-bound concentrations","volume":"58","author":"Patsalos","year":"2017","journal-title":"Epilepsia."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clpt.2005.10.002","article-title":"A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants","volume":"79","author":"Sim","year":"2006","journal-title":"Clin Pharmacol Ther."},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2125.2007.03057.x","article-title":"Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population","volume":"65","author":"Sugimoto","year":"2008","journal-title":"Br J Clin Pharmacol."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000676","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T22:37:51Z","timestamp":1692052671000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000676","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}